BC Innovations | Sep 13, 2012
Tools & Techniques

Probing for a point-of-care TB test

Existing tests to screen patients for tuberculosis are impractical in the point-of-care setting as they are either too slow, lack sensitivity or require specialized lab equipment. 1,2 Researchers at Stanford University and Texas A&M University...
BC Week In Review | Jul 26, 2010
Clinical News

Cubicin daptomycin: Phase II data

In an open-label Phase II safety trial in 74 patients, once-daily 6 and 8 mg doses of IV Cubicin for about 6 weeks following surgery to remove an infected prosthetic joint were safe and led...
BioCentury | Aug 17, 2009
Emerging Company Profile

Calixa: Bettering cephalosporin

Calixa Therapeutics Inc. is developing an in-licensed cephalosporin it says is more potent against multi-drug resistant strains of Pseudomonas aeruginosa than all other available beta lactams. The lead compound, CXA-101 , and two follow-ons are in...
BC Innovations | Mar 12, 2009
Targets & Mechanisms

Ganging up on TB

Work by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that two FDA-approved antibiotics-meropenem and clavulanate-could be used in combination to overcome drug-resistant Mycobacterium tuberculosis . 1 Although the fact that meropenem must...
BC Week In Review | Oct 29, 2007
Clinical News

P1A: Phase IIb data

In a double-blind Phase IIb trial in 112 patients receiving ampicillin for serious respiratory infections, P1A met both primary endpoints of preserving intestinal microflora diversity and reducing antibiotic resistance. Patients in the P1A arm had...
BC Week In Review | Dec 11, 2006
Clinical News

P1A: Phase IIb started

Ipsat started a double-blind, placebo-controlled, Russian and Ukrainian Phase IIb trial in 100 patients to prevent damage to intestinal microflora caused by beta-lactam antibiotics administered to hospitalized patients with upper- and lower-respiratory tract infections. Patients...
BioCentury | Apr 11, 2005
Product Development

Not bound to onercept

Although Serono S.A. had believed the binding and structure of its onercept TNF-binding protein looked more appealing than existing anti- TNF alpha treatments, the company halted development of the compound in psoriasis after it proved...
BC Week In Review | Dec 13, 2004
Clinical News

Telavancin: Phase II FAST2 data

In the double-blind, international Phase II FAST 2 trial in 201 patients, those treated with once daily telavancin had clinical cure rates of 96.1% compared to 93.5% treated with standard therapy of twice-a -day vancomycin...
BC Extra | Dec 8, 2004
Clinical News

Theravance telavancin Phase II data

THRX said in the Phase II FAST 2 trial, its telavancin ( TD-6424 ) was non-inferior to standard therapy in clinically evaluable patients. In the double-blind, U.S. and South African trial in 201 patients with Gram-positive complicated...
BioCentury | Aug 23, 2004
Product Development

A Little Help from Ester

Penem antibiotics have been around since 1985, but all three on the global market must be given intravenously. Daiichi Suntory Pharma Co. Ltd. developed the first oral penem, faropenem sodium, which it launched in Japan...
Items per page:
1 - 10 of 27